Option exercises, 92,823-share sale for Adaptive (NASDAQ: ADPT) COO

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp President and COO Julie Rubinstein reported a series of option exercises and related share sales. Over March 3–5, 2026, she exercised fully or partially vested stock options into common stock and sold 92,823 shares in open-market transactions at prices reported around the mid-teens per share.

The sales were effected under a Rule 10b5-1 trading plan adopted on November 18, 2025, meaning they followed a prearranged schedule. After these transactions, Rubinstein held 575,235 shares of common stock directly. Reported sale prices are weighted averages of multiple trades, with ranges disclosed between $15.11 and $16.94 per share.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RUBINSTEIN JULIE

(Last) (First) (Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVE E

(Street)

SEATTLE WA 98109

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and COO

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		M(1)		14,722	A	$6.55	602,971	D
Common Stock	03/03/2026		M(1)		11,881	A	$12.14	614,852	D
Common Stock	03/03/2026		S(1)		24,423	D	$15.49(2)	590,429	D
Common Stock	03/03/2026		S(1)		6,518	D	$16.33(3)	583,911	D
Common Stock	03/04/2026		M(1)		14,722	A	$6.55	598,633	D
Common Stock	03/04/2026		M(1)		11,881	A	$12.14	610,514	D
Common Stock	03/04/2026		S(1)		30,941	D	$16.6(4)	579,573	D
Common Stock	03/05/2026		M(1)		14,722	A	$6.55	594,295	D
Common Stock	03/05/2026		M(1)		11,881	A	$12.14	606,176	D
Common Stock	03/05/2026		S(1)		30,941	D	$16(5)	575,235	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$6.55	03/03/2026		M(1)			14,722	(6)	02/07/2028	Common Stock	14,722	$0	180,603	D
Stock Option (right to buy)	$12.14	03/03/2026		M(1)			11,881	(7)	03/04/2032	Common Stock	11,881	$0	451,463	D
Stock Option (right to buy)	$6.55	03/04/2026		M(1)			14,722	(6)	02/07/2028	Common Stock	14,722	$0	165,881	D
Stock Option (right to buy)	$12.14	03/04/2026		M(1)			11,881	(6)	03/04/2032	Common Stock	11,881	$0	439,582	D
Stock Option (right to buy)	$6.55	03/05/2026		M(1)			14,722	(6)	02/07/2028	Common Stock	14,722	$0	151,159	D
Stock Option (right to buy)	$12.14	03/05/2026		M(1)			11,881	(6)	03/04/2032	Common Stock	11,881	$0	427,701	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

2. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.11 to $16.10, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

3. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.11 to $16.56, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

4. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.35 to $16.94, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

5. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.74 to $16.30, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

6. The option is fully vested and exercisable.

7. The options vested with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

	/s/ Julie Rubinstein by Kyle Piskel, Attorney-in-Fact	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did ADPT executive Julie Rubinstein report on this Form 4?

Julie Rubinstein, President and COO of Adaptive Biotechnologies (ADPT), exercised stock options and sold 92,823 common shares. The transactions combined option exercises with open-market sales executed over several days in early March 2026 at mid-teen share prices.

How many Adaptive Biotechnologies (ADPT) shares did Julie Rubinstein sell and at what prices?

Julie Rubinstein sold 92,823 ADPT shares in multiple open-market transactions. Reported prices are weighted averages of numerous trades, with disclosed ranges spanning from $15.11 to $16.94 per share across the sale dates in March 2026.

Were Julie Rubinstein’s ADPT share sales under a Rule 10b5-1 trading plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan. That plan was adopted on November 18, 2025, meaning the timing and size of trades were prearranged rather than decided at the moment of sale.

How many Adaptive Biotechnologies (ADPT) shares does Julie Rubinstein hold after these trades?

Following the reported transactions, Julie Rubinstein directly holds 575,235 shares of Adaptive Biotechnologies common stock. This figure reflects her updated direct ownership after exercising stock options and completing the disclosed open-market sales.

What types of securities were involved in Julie Rubinstein’s ADPT Form 4 transactions?

The Form 4 shows activity in both stock options and common stock. Rubinstein exercised options (stock options, right to buy) into common shares, then conducted open-market sales of portions of that common stock at weighted-average prices.

How are the option grants for ADPT’s Julie Rubinstein structured and vested?

One reported option is noted as fully vested and exercisable. Another vests with respect to one-quarter on March 4, 2023, with 1/48 of the shares vesting monthly thereafter for each full month of continuous service until fully vested.